These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 8697399)

  • 1. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
    Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
    Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    Kaplan LD; Straus DJ; Testa MA; Von Roenn J; Dezube BJ; Cooley TP; Herndier B; Northfelt DW; Huang J; Tulpule A; Levine AM
    N Engl J Med; 1997 Jun; 336(23):1641-8. PubMed ID: 9171066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
    Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
    Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
    Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
    J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma.
    Canellos GP; Skarin AT; Klatt MM; Rosenthal DS; Case DC; Pinkus GS; Jochelson MS; Yeap BY; Shipp MA
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):2-7. PubMed ID: 2438777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
    Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
    Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
    Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma.
    Walsh C; Wernz JC; Levine A; Rarick M; Willson E; Melendez D; Bonnem E; Thompson J; Shelton B
    J Acquir Immune Defic Syndr (1988); 1993 Mar; 6(3):265-71. PubMed ID: 7680712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations.
    Connors JM; Klimo P
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):41-6. PubMed ID: 2456622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Hodgkin's lymphoma associated with the acquired immunodeficiency syndrome.
    Cáceres W
    Bol Asoc Med P R; 1995; 87(10-12):158-61. PubMed ID: 8924158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.